Magnesium levulinate

Identification

Name
Magnesium levulinate
Accession Number
DB14514  (DBSALT002481)
Type
Small Molecule
Groups
Nutraceutical
Description
Not Available
Structure
Thumb
Synonyms
  • Magnesium diasporal
Categories
UNII
DU3I0H5Z4H
CAS number
58505-81-0
Weight
Average: 254.521
Monoisotopic: 254.06407987
Chemical Formula
C10H14MgO6
InChI Key
RECCGACJWKEPOU-UHFFFAOYSA-L
InChI
InChI=1S/2C5H8O3.Mg/c2*1-4(6)2-3-5(7)8;/h2*2-3H2,1H3,(H,7,8);/q;;+2/p-2
IUPAC Name
magnesium(2+) bis(4-oxopentanoate)
SMILES
[Mg++].CC(=O)CCC([O-])=O.CC(=O)CCC([O-])=O

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
USodium/potassium-transporting ATPase subunit alpha-1Not AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
1alpha-Hydroxyvitamin D5The serum concentration of Magnesium levulinate can be increased when it is combined with 1alpha-Hydroxyvitamin D5.
3-Aza-2,3-Dihydrogeranyl DiphosphateMagnesium levulinate can cause a decrease in the absorption of 3-Aza-2,3-Dihydrogeranyl Diphosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.
AgmatineThe risk or severity of hypotension and neuromuscular blockade can be increased when Agmatine is combined with Magnesium levulinate.
Alendronic acidMagnesium levulinate can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
AlfacalcidolThe serum concentration of Magnesium levulinate can be increased when it is combined with Alfacalcidol.
AmiodaroneThe risk or severity of hypotension and neuromuscular blockade can be increased when Amiodarone is combined with Magnesium levulinate.
AmlodipineThe risk or severity of hypotension and neuromuscular blockade can be increased when Amlodipine is combined with Magnesium levulinate.
AranidipineThe risk or severity of hypotension and neuromuscular blockade can be increased when Aranidipine is combined with Magnesium levulinate.
AzelnidipineThe risk or severity of hypotension and neuromuscular blockade can be increased when Azelnidipine is combined with Magnesium levulinate.
BarnidipineThe risk or severity of hypotension and neuromuscular blockade can be increased when Barnidipine is combined with Magnesium levulinate.
Food Interactions
Not Available

References

General References
Not Available
External Links
ChemSpider
9761676
ChEMBL
CHEMBL3707302
Wikipedia
Magnesium_levulinate
ATC Codes
A12CC07 — Magnesium levulinate

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility1.22 mg/mLALOGPS
logP0.82ALOGPS
logP-0.069ChemAxon
logS-2.3ALOGPS
pKa (Strongest Acidic)4.32ChemAxon
pKa (Strongest Basic)-7.3ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area57.2 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity37.93 m3·mol-1ChemAxon
Polarizability10.79 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as gamma-keto acids and derivatives. These are organic compounds containing an aldehyde substituted with a keto group on the C4 carbon atom.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Keto acids and derivatives
Sub Class
Gamma-keto acids and derivatives
Direct Parent
Gamma-keto acids and derivatives
Alternative Parents
Short-chain keto acids and derivatives / Ketones / Carboxylic acid salts / Monocarboxylic acids and derivatives / Carboxylic acids / Organic salts / Organic oxides / Hydrocarbon derivatives / Organic cations
Substituents
Gamma-keto acid / Short-chain keto acid / Ketone / Carboxylic acid salt / Monocarboxylic acid or derivatives / Carboxylic acid / Carboxylic acid derivative / Organic oxygen compound / Organic oxide / Hydrocarbon derivative
Molecular Framework
Not Available
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Steroid hormone binding
Specific Function
This is the catalytic component of the active enzyme, which catalyzes the hydrolysis of ATP coupled with the exchange of sodium and potassium ions across the plasma membrane. This action creates th...
Gene Name
ATP1A1
Uniprot ID
P05023
Uniprot Name
Sodium/potassium-transporting ATPase subunit alpha-1
Molecular Weight
112895.01 Da
References
  1. Buchachenko AL, Kuznetsov DA, Berdinskii VL: [New mechanisms of biological effects of electromagnetic fields]. Biofizika. 2006 May-Jun;51(3):545-52. [PubMed:16808357]
  2. Sirijovski N, Olsson U, Lundqvist J, Al-Karadaghi S, Willows RD, Hansson M: ATPase activity associated with the magnesium chelatase H-subunit of the chlorophyll biosynthetic pathway is an artefact. Biochem J. 2006 Dec 15;400(3):477-84. [PubMed:16928192]
  3. Balasubramaniyan V, Nalini N: Leptin alters brain adenosine triphosphatase activity in ethanol-mediated neurotoxicity in mice. Singapore Med J. 2006 Oct;47(10):864-8. [PubMed:16990961]
  4. Nogovitsina OR, Levitina EV: Neurological aspects of the clinical features, pathophysiology, and corrections of impairments in attention deficit hyperactivity disorder. Neurosci Behav Physiol. 2007 Mar;37(3):199-202. [PubMed:17294093]

Drug created on July 12, 2018 10:20 / Updated on November 02, 2018 07:53